Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

NCT03590652 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

23

Enrollment

OTHER

Sponsor class

Stopped The trial met its primary endpoint.

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG: Ixazomib
DRUG: Pomalidomide
DRUG: Dexamethasone
DRUG: Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)

Sponsor

University of California, San Diego

Collaborators

[object Object]
[object Object]
[object Object]